Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 0.68 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708661 | 1.00 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL6177052 | 0.85 | RAB9A (0.74) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL6177049 | 0.85 | RAB9A (0.74) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL30530488 | 0.84 | CYSLTR1 (0.57) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL10760847 | 0.84 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL919524 | 0.84 | CYSLTR1 (0.57) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL919522 | 0.84 | CYSLTR1 (0.57) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL10760844 | 0.84 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL8107515 | 0.83 | CYSLTR2 (0.70) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 | |
| SCHEMBL8107518 | 0.83 | CYSLTR2 (0.70) | CYSLTR2CYSLTR1RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999209-B1 | 2-SULFAMOYLBENZOIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2006-11-02 | — | — | EP | disclosed |
| CN-1195739-C | 2-sulfamoylbenzoic acid derivatives | KAKEN PHARMA CO LTD (JP) | 2005-04-06 | — | — | CN | disclosed |
| EP-0834510-B1 | Flavone derivative and medicine comprising the same | KOWA CO (JP) | 2005-02-23 | — | — | EP | disclosed |
| EP-0902007-B1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2003-11-05 | — | — | EP | disclosed |
| US-20020049228-A1 | 2-Sulfamoylbenzoic acid derivatives | KAKEN PHARMACEUTICALS | 2002-04-25 | — | — | US | disclosed |
| EP-0905133-B1 | Tetrazole derivatives as LTD4 and H1 antagonists | KOWA CO (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6376671-B1 | LEUKOTRIENE AND THROMBOXANE A2 ANTAGONISTIC AGENTS; ANTIALLERGIC AGENTS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6255321-B1 | ANTIALLERGENS; RESPIRATRORY SYSTEM DISORDERS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| US-6136848-A | ANTIALLERGENS; ASTHMA THERAPY | KOWA CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-6121286-A | ANTILEUKOTRIENE ACTIVITY AND ANTIHISTAMINIC ACTIVITY, FOR TREATING ASTHMA; COMPOUNDS SUCH AS 6-METHOXY-3-(2-(3-(2-QUINOLYLMETHOXY)BENZYL)TETRAZOLYL)QUINOLIN-2-ONE | KOWA CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0902007-A1 | CHALCONE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-03-17 | — | — | EP | disclosed |
| EP-0834510-A2 | Flavone derivative and medicine comprising the same | KOWA CO. LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
| EP-0533695-B1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5322847-A | Inhibit platelet activating factor, block leukotriene D4 receptors | PFIZER INC. (US) | 1994-06-21 | — | — | US | disclosed |
| US-5281593-A | Pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1994-01-25 | — | — | US | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| WO-1991017163-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0219308-B1 | 2-SUBSTITUTED QUINOLINES | MERCK FROSST CANADA INC. (CA) | 1991-10-23 | — | — | EP | disclosed |
| EP-0219307-A2 | 2-Substituted quinolines | MERCK FROSST CANADA INC. (CA) | 1987-04-22 | — | — | EP | disclosed |
| EP-0219308-A2 | 2-Substituted quinolines | MERCK FROSST CANADA INC. (CA) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049228-A1 | 2-Sulfamoylbenzoic acid derivatives | LTB4R2, LTB4R, CYSLTR2 | CYSLTR2 3/4885CYSLTR1 5/4885RAB9A 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.